Product Images Rizatriptan Benzoate
View Photos of Packaging, Labels & Appearance
- Label - lbl713352536
- Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1
- Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2
- Figure3 - rizatriptan fig3
- Chemical Structure - rizatriptan str
Product Label Images
The following 5 images provide visual information about the product associated with Rizatriptan Benzoate NDC 71335-2536 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl713352536
Each tablet contains 7.265 mg of Rizatriptan Benzoate, USP equivalent to 5 mg Rizatriptan. The medication is recommended to be stored at 20° to 25°C (68° to 77°F) and kept in a tight, light-resistant container. This pharmaceutical product is available in a package with 30 tablets and should be kept out of the reach of children. The medication is to be dispensed by pharmacists with the patient package inserts. Manufacturer information: Bryant Ranch Prepack, Inc. and Aurobindo Pharma Limited.*
Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1
This text discusses a Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours in pooled studies involving placebo and rizatriptan benzoate in doses of 5 mg and 10 mg. The data is derived from four placebo-controlled outpatient trials, indicating the efficacy of rizatriptan benzoate in treating headaches. Patients who did not achieve headache response within 2 hours or received additional treatment were censored at the 2-hour mark for the analysis.*
Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2
This text provides a figure showcasing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over 24 hours following the initial dose in pooled studies 1, 2, 3, and 4. The data presented includes the percentage of patients opting for a second dose at various time intervals. The plot is based on data from 4 placebo-controlled outpatient clinical trials and includes patients who had a headache response at 2 hours as well as those who did not respond to the initial dose. Remedication within 2 hours post-dose was not allowed.*
Figure3 - rizatriptan fig3
This description is not available.*
Chemical Structure - rizatriptan str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
